Skip to main content

Advertisement

SpringerLink
Log in

Specter of eye toxicity looms over BCMA-targeted therapy

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The first antibody–drug conjugate to treat multiple myeloma can spur reversible loss of vision, but that may not be the case for other anti-BCMA T-cell therapies or bispecific antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Somerville, MA, USA

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Specter of eye toxicity looms over BCMA-targeted therapy. Nat Biotechnol 38, 1363–1365 (2020). https://doi.org/10.1038/s41587-020-00757-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-00757-8

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation